Fennec Pharmaceuticals (FENC) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

—

Estimate

$0.02

Surprise

—

Score today

6.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

• B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18 — benzinga, 2026-08-12
• Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16 — benzinga, 2026-08-12
• Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate — benzinga, 2026-08-11

TrendMatrix currently rates FENC Hold at 6.5/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$10.35

Price target

$15.37

Stop

$9.71

Upside to target

+48.5%

Reward-to-risk

5.1:1

Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$362.9M

P/E (fwd)

10.9

52-week range

$5.65–$13.25

Off 52-week high

21.9%

RSI (14)

47

Volume vs avg

0.63×

Score today

6.5/10